Early Diagnosis of Parkinson’s Disease in New Neurological Patients by Testing of Visuo-Manual Coordination

  • S. Hocherman
  • N. Giladi
Part of the Advances in Behavioral Biology book series (ABBI, volume 47)


Most neurons of the substantia nigra pars compacta die before clinically detectable symptoms of Parkinson’s disease (PD) occur. Therefore, early detection of PD is critical for neuroprotective therapy (Jenner, 1993; Gerlach et al., 1995). Early onset of such therapy, when enough dopaminergic neurons are still intact, may have a significant impact on the quality and longevity of the patient’s life (Knoll, 1992; Shoulson, 1992; Tatton and Greenwood, 1991).


Model Path Target Circle Symptomatic Hand Pathological Range Routine Neurological Examination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berardelli, A., Accornero, N., Argenta, M., Meco, G., and Manfredi, M., 1986, Fast complex arm movements in parkinson’s disease, J. Neurol. Neurosurgery, Psychiatry. 49:1146–1149.CrossRefGoogle Scholar
  2. Gerlach, M., Riederer, P., Youdim, M.B.H., 1995, Neuroprotective therapeutic strategies comparison of experimental and clinical results, Biochem Pharmacol. 50(1): 1–16.PubMedCrossRefGoogle Scholar
  3. Jenner, P., 1993, Presymptomatic detection of Parkinson’s disease, J. Neural. Transm. Suppl. 40: 23–36Google Scholar
  4. Flowers, K. A., 1976, Visual ‘closed loop’ and ‘open loop’ characteristics of voluntary movement in patients with parkinsonism and intention tremor, Brain 99:269–310.PubMedCrossRefGoogle Scholar
  5. Hocherman, S., Aharon, J., 1994, Two dimensional tracing and tracking in patients with parkinson’s disease, Neurology 44:111–116.PubMedCrossRefGoogle Scholar
  6. Kirollos, C., O’Neill, C.J., Dobbs, R.J., Charlett, A., Bowes, S.G., Weiler, C., Purkiss, A.G., Hunt, W.B., and Dobbs, S.M., 1993, Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers, Age Ageing 22: 20–26.PubMedCrossRefGoogle Scholar
  7. Knoll, J., 1992, (−)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system, J. Am. Geriatr. Soc. 40(8):839–847.PubMedGoogle Scholar
  8. Montgomery, E.B.J., Nuessen, J., and Gorman, D.S., 1991, Reaction time and movement velocity abnormalities in Parkinson’s disease under different task conditions, Neurol. 41: 1476–1481.CrossRefGoogle Scholar
  9. Sanes, J.N., 1985, Information processing deficits in parkinson’s disease during movement, Neuropsychology 23,3:381–392.CrossRefGoogle Scholar
  10. Sheridan, M.R., Flowers, K.A., and Hurrell, J., 1987, Programming and execution of movement in parkinson’s disease, Brain 110:1247–1271.PubMedCrossRefGoogle Scholar
  11. Shoulson, I., 1992, An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. Eur. Neurol. 32(Suppl. l):46–53.CrossRefGoogle Scholar
  12. Tatton, W.G., Greenwood, C.E., 1991, Rescue of dying neurons: A new action of deprenyl in MPTP parkinsonism, J. Neurosci. Res. 30:666–672.PubMedCrossRefGoogle Scholar
  13. Teasdale, N., Phillips, J., and Stelmach, G.E., 1990, Temporal movement control in patients with parkinson’s disease, J. Neurol. Neurosurgery. Psychiatry 53:862–868.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • S. Hocherman
    • 1
  • N. Giladi
    • 2
  1. 1.TechnionHaifaIsrael
  2. 2.Department of NeurologyCarmel HospitalHaifaIsrael

Personalised recommendations